443 related articles for article (PubMed ID: 29584597)
1. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
Nakamura Y; Kawaoka T; Higaki T; Fukumoto W; Honda Y; Iida M; Fujioka C; Kiguchi M; Aikata H; Chayama K; Awai K
Eur J Radiol; 2018 Jan; 98():41-49. PubMed ID: 29279169
[TBL] [Abstract][Full Text] [Related]
3. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: CT texture analysis as a predictor of survival after surgical resection.
Brenet Defour L; Mulé S; Tenenhaus A; Piardi T; Sommacale D; Hoeffel C; Thiéfin G
Eur Radiol; 2019 Mar; 29(3):1231-1239. PubMed ID: 30159621
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
6. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
Patchett N; Furlan A; Marsh JW
Jpn J Clin Oncol; 2016 Sep; 46(9):839-44. PubMed ID: 27317737
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma: Texture Analysis of Preoperative Computed Tomography Images Can Provide Markers of Tumor Grade and Disease-Free Survival.
Oh J; Lee JM; Park J; Joo I; Yoon JH; Lee DH; Ganeshan B; Han JK
Korean J Radiol; 2019 Apr; 20(4):569-579. PubMed ID: 30887739
[TBL] [Abstract][Full Text] [Related]
8. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
9. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
10. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
[TBL] [Abstract][Full Text] [Related]
11. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
15. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
[TBL] [Abstract][Full Text] [Related]
16. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.
Lubner MG; Stabo N; Abel EJ; Del Rio AM; Pickhardt PJ
AJR Am J Roentgenol; 2016 Jul; 207(1):96-105. PubMed ID: 27145377
[TBL] [Abstract][Full Text] [Related]
17. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes.
Lubner MG; Stabo N; Lubner SJ; del Rio AM; Song C; Halberg RB; Pickhardt PJ
Abdom Imaging; 2015 Oct; 40(7):2331-7. PubMed ID: 25968046
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
19.
Sung PS; Park HL; Yang K; Hwang S; Song MJ; Jang JW; Choi JY; Yoon SK; Yoo IR; Bae SH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):384-391. PubMed ID: 29124280
[TBL] [Abstract][Full Text] [Related]
20. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.
Ng F; Ganeshan B; Kozarski R; Miles KA; Goh V
Radiology; 2013 Jan; 266(1):177-84. PubMed ID: 23151829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
